[go: up one dir, main page]

CL2024002067A1 - Inhibidores y métodos de uso de kcnt1 - Google Patents

Inhibidores y métodos de uso de kcnt1

Info

Publication number
CL2024002067A1
CL2024002067A1 CL2024002067A CL2024002067A CL2024002067A1 CL 2024002067 A1 CL2024002067 A1 CL 2024002067A1 CL 2024002067 A CL2024002067 A CL 2024002067A CL 2024002067 A CL2024002067 A CL 2024002067A CL 2024002067 A1 CL2024002067 A1 CL 2024002067A1
Authority
CL
Chile
Prior art keywords
kcnt1
methods
disease
inhibitors
disorder
Prior art date
Application number
CL2024002067A
Other languages
English (en)
Inventor
Martinez Botella Gabriel
Mark Griffin Andrew
S Charifson Paul
Reddy Kiran
Kristopher Mathieu Kahlig Michael
Edward Marron Brian
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of CL2024002067A1 publication Critical patent/CL2024002067A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida, en parte, a compuestos y composiciones útiles para prevenir y / o tratar una enfermedad o trastorno neurológico, una enfermedad o afección relacionada con una excitabilidad neuronal excesiva y / o una mutación de ganancia de función en un gen (por ejemplo, KCNT1). También se proporcionan en el presente documento métodos para tratar una enfermedad o trastorno neurológico, una enfermedad o afección relacionada con una excitabilidad neuronal excesiva y / o una mutación de ganancia de función en un gen tal como KCNT1.
CL2024002067A 2019-05-03 2024-07-08 Inhibidores y métodos de uso de kcnt1 CL2024002067A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US202062982864P 2020-02-28 2020-02-28

Publications (1)

Publication Number Publication Date
CL2024002067A1 true CL2024002067A1 (es) 2024-12-13

Family

ID=73051241

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021002877A CL2021002877A1 (es) 2019-05-03 2021-11-02 Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos
CL2024002067A CL2024002067A1 (es) 2019-05-03 2024-07-08 Inhibidores y métodos de uso de kcnt1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2021002877A CL2021002877A1 (es) 2019-05-03 2021-11-02 Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos

Country Status (17)

Country Link
US (1) US20220259193A1 (es)
EP (1) EP3962481A4 (es)
JP (2) JP7667573B2 (es)
KR (1) KR20220016086A (es)
CN (2) CN120817941A (es)
AU (1) AU2020267356B2 (es)
BR (1) BR112021022067A2 (es)
CA (1) CA3139063A1 (es)
CL (2) CL2021002877A1 (es)
CO (1) CO2021016471A2 (es)
EC (1) ECSP21087884A (es)
IL (1) IL287768A (es)
MX (1) MX2021013421A (es)
PE (1) PE20220016A1 (es)
SA (1) SA521430751B1 (es)
SG (1) SG11202112158YA (es)
WO (1) WO2020227101A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220280476A1 (en) * 2019-05-03 2022-09-08 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
JP7699836B2 (ja) * 2020-02-28 2025-06-30 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｋｃｎｔ１阻害剤、および使用方法
WO2022056042A1 (en) * 2020-09-09 2022-03-17 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2022111605A1 (zh) * 2020-11-27 2022-06-02 瑞石生物医药有限公司 芳基或杂芳基取代五元芳杂环化合物及其用途
WO2022140547A2 (en) * 2020-12-22 2022-06-30 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231873A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
EP4536644A1 (en) * 2022-06-08 2025-04-16 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
CN116813505B (zh) * 2023-06-29 2025-09-02 爱斯特（成都）生物制药股份有限公司 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法
WO2025117662A1 (en) * 2023-11-29 2025-06-05 Actio Biosciences, Inc. Heterocyclic compounds useful as kcnt1 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2005060255A (ja) * 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20080021217A1 (en) * 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
PE20151939A1 (es) * 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
KR102307037B1 (ko) 2014-09-29 2021-09-30 더 스크립스 리서치 인스티튜트 심폐 장애들의 치료를 위한 스핑고신-1-포스페이트 수용체 조절제들
EP3275440B1 (en) * 2015-03-25 2022-05-04 National Center for Geriatrics and Gerontology Novel oxadiazole derivative and pharmaceutical containing same
EP3438091A4 (en) * 2016-03-30 2019-11-27 Ajinomoto Co., Inc. CONNECTION WITH INCREASING ACTIVITY FOR ACTION OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR
US11731966B2 (en) * 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
JP7699836B2 (ja) * 2020-02-28 2025-06-30 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｋｃｎｔ１阻害剤、および使用方法
IL296649A (en) * 2020-03-23 2022-11-01 Praxis Prec Medicines Inc Kcnt1 inhibitors and methods of use
EP4175624A4 (en) * 2020-07-06 2024-08-07 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11773088B2 (en) * 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2022140547A2 (en) * 2020-12-22 2022-06-30 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231873A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Also Published As

Publication number Publication date
US20220259193A1 (en) 2022-08-18
BR112021022067A2 (pt) 2022-05-17
KR20220016086A (ko) 2022-02-08
WO2020227101A1 (en) 2020-11-12
JP7667573B2 (ja) 2025-04-23
IL287768A (en) 2022-01-01
MX2021013421A (es) 2022-02-11
ECSP21087884A (es) 2022-01-31
AU2020267356A1 (en) 2022-01-06
CA3139063A1 (en) 2020-11-12
JP2022531388A (ja) 2022-07-06
JP2025102975A (ja) 2025-07-08
CO2021016471A2 (es) 2022-04-08
SA521430751B1 (ar) 2024-02-01
EP3962481A1 (en) 2022-03-09
EP3962481A4 (en) 2023-03-22
CL2021002877A1 (es) 2022-08-12
AU2020267356B2 (en) 2025-04-24
CN120817941A (zh) 2025-10-21
CN114269340A (zh) 2022-04-01
SG11202112158YA (en) 2021-12-30
PE20220016A1 (es) 2022-01-11

Similar Documents

Publication Publication Date Title
CL2024002067A1 (es) Inhibidores y métodos de uso de kcnt1
ECSP21087657A (es) Inhibidores de kcnt1 y métodos de uso
CO2021000151A2 (es) Inhibidores de pd-1/pd-l1
BR112022019041A2 (pt) Inibidores de kcnt1 e métodos de uso
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MA43131B1 (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
MX2023011933A (es) Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos.
MX2020012561A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas.
ECSP21080096A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra
BR112022017191A2 (pt) Inibidores de kcnt1 e métodos de uso
CO2024009571A2 (es) Inhibidores de parp1
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
MX2022003671A (es) Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades.
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
CL2023003811A1 (es) Oligonucleótidos antisentido pikfyve
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
WO2022140547A3 (en) Kcnt1 inhibitors and methods of use
MX2023000360A (es) Inhibidores de kcnt1 y metodos de uso.
MX2022006308A (es) Derivados de carbazol polimorfos y usos de los mismos.